Basic Information
Aimovig
Regulatory Information
EMEA/H/C/004447
Authorised
July 26, 2018
June 1, 2018
12
August 14, 2023
Company Information
Ireland
Vista Building Elm Park, Merrion Road Dublin 4
NOVARTIS EUROPHARM LIMITED
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Aimovig is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month when initiating treatment with Aimovig.
Overview Summary
Aimovig is a medicine used to prevent migraine in adults who have migraines at least 4 days a month. Aimovig contains the active substance erenumab.